Abstract | BACKGROUND: METHODS: Sixteen patients with metastatic urothelial cancer, previously treated with a platinum-based regimen, were studied. GC ( gemcitabine 750 mg/m(2), on days 1, 8, and 15; carboplatin 200 mg/m(2), on day 2) was administered every 28 days to 15 patients. GDC ( gemcitabine 750 mg/m(2), on days 1 and 8; docetaxel 50 mg/m(2), on day 1; carboplatin 200 mg/m(2) on day 1) was administered every 21 days to 9 patients. Eight of the 9 GDC-treated patients had earlier been treated with GC and had become refractory. RESULTS: With the GC therapy, 7 of the 15 treated patients (47%; 95% confidence interval, 21%-73%) showed an objective response, with 3 achieving a clinical complete response (CR) and 4 a partial response (PR). With the GDC therapy, 6 of the 9 treated patients (67%; 95% confidence interval, 29%-92%) showed an objective response, with 1 achieving CR and 5, PR. Five of the 8 (63%) GC-refractory patients responded to GDC therapy. The median duration of response was 4 months (range, 2-10+ months) on GC therapy, and 3 months (range, 3-5 months) on GDC therapy. Toxicities associated with GC were less than those with GDC. CONCLUSION:
|
Authors | Senji Hoshi, Chikara Ohyama, Kunio Ono, Atsushi Takeda, Shinichi Yamashita, Takashi Yamato, Akihiro Itoh, Makoto Satoh, Seiichi Saito, Yasuhiro Okada, Fumihiko Sohma, Yoichi Arai |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 9
Issue 2
Pg. 125-9
(Apr 2004)
ISSN: 1341-9625 [Print] Japan |
PMID | 15108045
(Publication Type: Journal Article)
|
Chemical References |
- Taxoids
- Deoxycytidine
- Docetaxel
- Carboplatin
- Gemcitabine
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Docetaxel
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Pilot Projects
- Taxoids
(administration & dosage)
- Treatment Outcome
- Ureteral Neoplasms
(drug therapy, pathology)
- Urinary Bladder Neoplasms
(drug therapy, pathology)
- Gemcitabine
|